Michael Shleifer, Ph.D. Interim Chief Executive Officer and Founder
Founder and Managing Partner of SPRIM with 20 year experience in the healthcare sector
Co-founder of SPRIM Ventures, which formed TKS1 in partnership with Tikehau Capital, a healthcare and life science focused venture fund
Board member in multiple startups
Long experience in Pharmaceuticals and Medtech
Doctorate from Université Rene Descartes Paris V and a Master Political Science from Sciences Po Paris
Laurent Benissan Chief Financial Officer and Founder
Founder of Silhouette Lift, an innovative medical device company in the aesthetic field. Started the company in 2007 and developed a cutting edge technology used for minimally invasive facial rejuvenation. In 2014, Silhouette Lift was sold to Sinclair IS Pharma, a public company in the UK
Spent the first 15 years of his career in investment banking, working for Merrill Lynch and other international firms
Master in management from HEC business school in France
Dr. Richard Gelling Chief Scientific Officer
Over 20 years R&D management experience, across North America, Europe and Southeast Asia.
Extensive hands on management experience in all aspects . in the Pharmaceutical, Nutrition and Consumer Healthcare product development, across a wide range of disease and health benefit areas.
Doctorate from the University of British Columbia, in the Department of Physiology, Vancouver, Canada
Over 10 years of work experience in scientific research, medical affairs and clinical studies in Asia
MD from Guangxi Medical University in China, trained endocrinologist and practised in China
Doctorate in Chemistry specializing in the area of Food Science & Nutrition from National University of Singapore, and postdoctoral training in National University Hospital
Prof David L. Silver Scientific Founder and Advisor
Professor and Deputy Director of the Signature Research Program in Cardiovascular & Metabolic Disorders at Duke-NUS Medical School, Singapore.
Research focus on molecular nutrition and role of lipids in brain and eye function and health. Discoverer of the Mfsd2a-LPC pathway.
Doctorate in Genetics from University of Michigan and postdoctoral training in cardiovascular and lipid research at Columbia University. Held tenure-track faculty appointments at Columbia University and the Albert Einstein College of Medicine, USA.
Douglas C. Hicks Chief Business Officer
20+ years of operational, business development, and corporate strategy leadership in the biotech and pharmaceutical industry
Experience with start-up, midsize, and large companies – iBio, Inc. (NYSE MKT: IBIO); Clearview Projects, Inc; Bristol-Myers Squibb
Led or advised on the execution of over 50 transactions with an overall deal value exceeding $700M
MBA with a focus on finance and strategy from Pennsylvania State University